Daniel Ontaneda

List of Publications by Year
in descending order

90 papers	2,902 citations	218677 26 h-index	182427 51 g-index
91 all docs	91 docs citations	91 times ranked	4214 citing authors

#	Article	IF	Citations
1	The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative. Nature Reviews Neurology, 2016, 12, 714-722.	10.1	274
2	Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function. Lancet, The, 2017, 389, 1357-1366.	13.7	235
3	Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis. New England Journal of Medicine, 2018, 379, 846-855.	27.0	201
4	Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. Lancet Neurology, The, 2015, 14, 208-223.	10.2	188
5	Cell-based therapeutic strategies for multiple sclerosis. Brain, 2017, 140, 2776-2796.	7.6	139
6	Measuring Myelin Repair and Axonal Loss with Diffusion Tensor Imaging. American Journal of Neuroradiology, 2011, 32, 85-91.	2.4	127
7	Cortical neuronal densities and cerebral white matter demyelination in multiple sclerosis: a retrospective study. Lancet Neurology, The, 2018, 17, 870-884.	10.2	103
8	Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis. Lancet Neurology, The, 2019, 18, 973-980.	10.2	99
9	T1â€/T2â€weighted ratio differs in demyelinated cortex in multiple sclerosis. Annals of Neurology, 2017, 82, 635-639.	5.3	82
10	Revisiting The Multiple Sclerosis Functional Composite: proceedings from the National Multiple Sclerosis Society (NMSS) Task Force on Clinical Disability Measures. Multiple Sclerosis Journal, 2012, 18, 1074-1080.	3.0	67
11	Progressive multiple sclerosis. Current Opinion in Neurology, 2015, 28, 237-243.	3.6	65
12	Multiple Sclerosis: New Insights in Pathogenesis and Novel Therapeutics. Annual Review of Medicine, 2012, 63, 389-404.	12.2	64
13	Multiple sclerosis management during the COVID-19 pandemic. Multiple Sclerosis Journal, 2020, 26, 1163-1171.	3.0	63
14	Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis. Contemporary Clinical Trials, 2016, 50, 166-177.	1.8	59
15	Diagnosis and Management of Progressive Multiple Sclerosis. Biomedicines, 2019, 7, 56.	3.2	53
16	Imaging outcome measures of neuroprotection and repair in MS. Neurology, 2019, 92, 519-533.	1.1	53
17	Imaging as an Outcome Measure in Multiple Sclerosis. Neurotherapeutics, 2017, 14, 24-34.	4.4	50
18	Diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm. Multiple Sclerosis Journal, 2018, 24, 750-757.	3.0	50

#	Article	IF	Citations
19	Early tolerability and safety of fingolimod in clinical practice. Journal of the Neurological Sciences, 2012, 323, 167-172.	0.6	44
20	Is neuromyelitis optica with advanced age of onset a paraneoplastic disorder?. International Journal of Neuroscience, 2014, 124, 509-511.	1.6	43
21	Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up. Multiple Sclerosis and Related Disorders, 2016, 10, 44-52.	2.0	43
22	Relapse rates in patients with multiple sclerosis treated with fingolimod: Subgroup analyses of pooled data from three phase 3 trials. Multiple Sclerosis and Related Disorders, 2016, 8, 124-130.	2.0	37
23	Multiple sclerosis risk factors contribute to onset heterogeneity. Multiple Sclerosis and Related Disorders, 2019, 28, 11-16.	2.0	36
24	New diagnosis of multiple sclerosis in the setting of mRNA COVID-19 vaccine exposure. Journal of Neuroimmunology, 2022, 362, 577785.	2.3	34
25	Intrinsic and Extrinsic Mechanisms of Thalamic Pathology in Multiple Sclerosis. Annals of Neurology, 2020, 88, 81-92.	5.3	33
26	Clinical outcome measures for progressive MS trials. Multiple Sclerosis Journal, 2017, 23, 1627-1635.	3.0	32
27	Experience with fingolimod in clinical practice. International Journal of Neuroscience, 2015, 125, 678-685.	1.6	31
28	Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: The DELIVER-MS study protocol. Contemporary Clinical Trials, 2020, 95, 106009.	1.8	31
29	Deep grey matter injury in multiple sclerosis: a NAIMS consensus statement. Brain, 2021, 144, 1974-1984.	7.6	31
30	Association of Disease Severity and Socioeconomic Status in Black and White Americans With Multiple Sclerosis. Neurology, 2021, 97, e881-e889.	1.1	30
31	Automated Integration of Multimodal MRI for the Probabilistic Detection of the Central Vein Sign in White Matter Lesions. American Journal of Neuroradiology, 2018, 39, 1806-1813.	2.4	29
32	Thalamic Injury and Cognition in Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 623914.	2.4	28
33	Cognitive processing speed in multiple sclerosis clinical practice: association with patientâ€reported outcomes, employment and magnetic resonance imaging metrics. European Journal of Neurology, 2020, 27, 1238-1249.	3.3	26
34	Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers. Neurology: Clinical Practice, 2018, 8, 292-301.	1.6	25
35	Imaging Mechanisms of Disease Progression in Multiple Sclerosis: Beyond Brain Atrophy. Journal of Neuroimaging, 2020, 30, 251-266.	2.0	24
36	The Role of Advanced Magnetic Resonance Imaging Techniques in Multiple Sclerosis Clinical Trials. Neurotherapeutics, 2017, 14, 905-923.	4.4	23

#	Article	IF	Citations
37	Central vein sign: A diagnostic biomarker in multiple sclerosis (CAVS-MS) study protocol for a prospective multicenter trial. NeuroImage: Clinical, 2021, 32, 102834.	2.7	23
38	Identifying the Start of Multiple Sclerosis Injury: A Serial DTI Study. Journal of Neuroimaging, 2014, 24, 569-576.	2.0	21
39	Measuring Brain Tissue Integrity during 4 Years Using Diffusion Tensor Imaging. American Journal of Neuroradiology, 2017, 38, 31-38.	2.4	20
40	Sensitivity of T1/T2-weighted ratio in detection of cortical demyelination is similar to magnetization transfer ratio using post-mortem MRI. Multiple Sclerosis Journal, 2022, 28, 198-205.	3.0	18
41	Risk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple Sclerosis. CNS Drugs, 2015, 29, 759-771.	5.9	16
42	MOG-related disorders: A new cause of imaging-negative myelitis?. Multiple Sclerosis Journal, 2020, 26, 511-515.	3.0	15
43	Progressive Multiple Sclerosis. CONTINUUM Lifelong Learning in Neurology, 2019, 25, 736-752.	0.8	15
44	Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up. Journal of the Neurological Sciences, 2019, 407, 116498.	0.6	14
45	Comprehensive Autopsy Program for Individuals with Multiple Sclerosis. Journal of Visualized Experiments, 2019, , .	0.3	12
46	Technology-enabled assessments to enhance multiple sclerosis clinical care and research. Neurology: Clinical Practice, 2020, 10, 222-231.	1.6	12
47	Vitamin D and MRI measures in progressive multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 35, 276-282.	2.0	11
48	Technology-enabled comprehensive characterization of multiple sclerosis in clinical practice. Multiple Sclerosis and Related Disorders, 2020, 38, 101525.	2.0	11
49	Controversial association between leptomeningeal enhancement and demyelinated cortical lesions in multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 135-136.	3.0	11
50	Predicting disability worsening in relapsing and progressive multiple sclerosis. Current Opinion in Neurology, 2021, 34, 312-321.	3.6	9
51	Tuberculosis screening in multiple sclerosis: effect of disease-modifying therapies and lymphopenia on the prevalence of indeterminate TB screening results in the clinical setting. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731987546.	1.0	8
52	Exploratory MRI measures after intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731985603.	1.0	8
53	Camptocormia and Pisa syndrome as manifestations of acute myasthenia gravis exacerbation. Journal of the Neurological Sciences, 2015, 359, 8-10.	0.6	7
54	Serum neurofilament light chain concentration in a phase 1/2 trial of autologous mesenchymal stem cell transplantation. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731988719.	1.0	7

#	Article	IF	Citations
55	Pregnancy and multiple sclerosis: Risk of unplanned pregnancy and drug exposure in utero. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731989174.	1.0	7
56	Measures of Thalamic Integrity are Associated with Cognitive Functioning in Fingolimod-treated Multiple Sclerosis Patients. Multiple Sclerosis and Related Disorders, 2021, 47, 102635.	2.0	7
57	MS progression is predominantly driven by age-related mechanisms â€“ NO. Multiple Sclerosis Journal, 2019, 25, 904-906.	3.0	6
58	Palatal myoclonus, abnormal eye movements, and olivary hypertrophy in GAD65-related disorder. Neurology, 2020, 94, 273-275.	1.1	6
59	Comorbidity effect on processing speed test and MRI measures in multiple sclerosis patients. Multiple Sclerosis and Related Disorders, 2020, 46, 102593.	2.0	6
60	T1/T2-weighted ratio is a surrogate marker of demyelination in multiple sclerosisâ€”yes. Multiple Sclerosis Journal, 2022, 28, 352-354.	3.0	6
61	Association of socioeconomic disadvantage and neighborhood disparities with clinical outcomes in multiple sclerosis patients. Multiple Sclerosis and Related Disorders, 2022, 61, 103734.	2.0	6
62	Treating primary-progressive multiple sclerosis: potential of ocrelizumab and review of B-cell therapies. Degenerative Neurological and Neuromuscular Disease, 2017, Volume 7, 31-45.	1.3	5
63	Juxtacortical susceptibility changes in progressive multifocal leukoencephalopathy at the grayâ€“white matter junction correlates with iron-enriched macrophages. Multiple Sclerosis Journal, 2021, 27, 135245852199965.	3.0	5
64	Vitamin D Levels and Visual System Measurements in Progressive Multiple Sclerosis. International Journal of MS Care, 2021, 23, 53-58.	1.0	5
65	Visual imaging as a predictor of neurodegeneration in experimental autoimmune demyelination and multiple sclerosis. Acta Neuropathologica Communications, 2022, 10, .	5.2	5
66	The benefits and risks of alemtuzumab in multiple sclerosis. Expert Review of Clinical Immunology, 2013, 9, 189-191.	3.0	4
67	Pembrolizumab-Induced CNS Vasculitis. Neurology: Clinical Practice, 2021, 11, e30-e32.	1.6	4
68	Clinical commentary on â€œWarts and all: Fingolimod and unusual HPV associated lesionsâ€• Multiple Sclerosis Journal, 2019, 25, 1550-1552.	3.0	4
69	Novel de novo TREX1 mutation in a patient with retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations mimicking demyelinating disease. Multiple Sclerosis and Related Disorders, 2021, 52, 103015.	2.0	4
70	Is computerized screening for processing speed impairment sufficient for identifying MS-related cognitive impairment in a clinical setting?. Multiple Sclerosis and Related Disorders, 2021, 54, 103106.	2.0	4
71	Slowly Expanding Lesions. Neurology, 2022, 98, 699-700.	1.1	4
72	Inadequate outcome measures are the biggest impediment to successful clinical trials in progressive MS â€“ Commentary. Multiple Sclerosis Journal, 2017, 23, 508-509.	3.0	3

#	Article	IF	Citations
73	Stem cell injection-induced glioneuronal lesion of the cauda equina. Neurology, 2018, 90, 613-615.	1.1	3
74	Identifying a new subtype of multiple sclerosis. Neurodegenerative Disease Management, 2018, 8, 367-369.	2.2	3
75	Keep the Worms in the Mud. JAMA Neurology, 2020, 77, 1066.	9.0	3
76	Pragmatic clinical trials for treating relapsing multiple sclerosis. Lancet Neurology, The, 2019, 18, 1075.	10.2	2
77	Decentralised clinical trials in multiple sclerosis research. Multiple Sclerosis Journal, 2023, 29, 317-325.	3.0	2
78	Multiple Sclerosis Treatment. CONTINUUM Lifelong Learning in Neurology, 2013, 19, 1092-1099.	0.8	1
79	Diffusion tensor imaging before, during and after progressive multifocal leukoencephalopathy. European Journal of Neurology, 2014, 21, e36-8.	3.3	1
80	Treatment decisions in MS: Shifting the goal posts or changing how we see them?. Multiple Sclerosis Journal, 2018, 24, 1523-1525.	3.0	1
81	Clinical observation during alemtuzumab administration. Multiple Sclerosis and Related Disorders, 2020, 37, 101412.	2.0	1
82	Fourteen-year serial MRIs of patients with mild and severe courses of MS. Neurology: Clinical Practice, 2020, 10, e5-e6.	1.6	1
83	Detection of central vein should be part of MS diagnostic criteria â€“ Yes. Multiple Sclerosis Journal, 2020, 26, 405-406.	3.0	1
84	Achieving effective patient and public involvement in international clinical trials in neurology. Neurology: Clinical Practice, 2020, 10, 265-272.	1.6	1
85	Integrating patient-reported outcomes and quantitative timed tasks to identify relapsing remitting multiple sclerosis patient subgroups: a latent profile analysis. Multiple Sclerosis and Related Disorders, 2021, 51, 102912.	2.0	1
86	The challenges and opportunities of multiple sclerosis care in Latin America. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2017, 3, 205521731772084.	1.0	0
87	Prevalence of multiple sclerosis in Cuenca, Ecuador. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731988495.	1.0	0
88	Prediction in treatment outcomes in multiple sclerosis: challenges and recent advances. Expert Review of Clinical Immunology, 2021, 17, 1187-1198.	3.0	0
89	MRI, Big Data, and Artificial Intelligence. Neurology, 2021, 97, 975-976.	1.1	0
90	Propensity methods for multiple sclerosis: The devil is in the details. Multiple Sclerosis Journal, 2016, 22, 1248-1249.	3.0	0